All Resources

Position Statement: Bone Conduction Hearing Devices

Position Statement: Bone Conduction Hearing Devices

The American Academy of Otolaryngology-Head and Neck Surgery considers bone conduction hearing devices (BCHD) as appropriate, and in some cases preferred, for the treatment of conductive and mixed hearing loss.  BCHD may also be indicated in select patients with single-sided deafness. BCHD include semi-implantable bone conduction devices utilizing either a percutaneous or transcutaneous attachment, as well as bone conduction oral appliances and scalp-worn devices. The recommendation for BCHD should be determined by a qualified otolaryngology-head and neck surgeon.  These devices are approved by the Food and Drug Administration (FDA) for these indications, and their use should adhere to the restrictions and guidelines specified by the appropriate governing agency, such as the FDA in the United States and the respective regulatory agencies in countries other than the United States.

Drafted 3/13/2016
Reviewed 9/17/2016
Revised 4/13/2021

References:

  1. Crowson MG, Tucci DL. Mini review of the cost-effectiveness of unilateral osseointegrated implants in adults: Possibly cost-effective for the correct indication. Audiol Neurotol 2016;21(2):69-71.
  2. Baker S, Centric A, Chenupati SK. Innovation in abutment-free bone-anchored hearing devices in children: Updated results and experience. Int J Pediatr Otorhinolaryngol 2015;79(10):1667-72.
  3. Saroul N, Akkari M, Pavier Y, et al. Long-term benefit and sound localization in patients with singlesided deafness rehabilitated with an osseointegrated bone-conduction device. Otol Neurotol 2013;34(1):111-4.
  4. Monksfield P, Jowett S, Reid A, et al. Cost-effectiveness analysis of the bone-anchored hearing device. Otol Neurotol 2011:32:1192-97.
  5. Lin LM, Bowditch S, Anderson MJ, et al. Amplification in the rehabilitation of unilateral deafness: speech in noise and directional hearing effects with bone-anchored hearing and contralateral routing of signal amplification. Otol Neurotol 2006; 27(2):172-82.

Important Disclaimer Notice (Updated 7/31/14)

Position statements are approved by the American Academy of Otolaryngology–Head and Neck Surgery or Foundation (AAO-HNS/F) Boards of Directors and are typically generated from AAO-HNS/F committees. Once approved by the Academy or Foundation Board of Directors, they become official position statements and are added to the existing position statement library. In no sense do they represent a standard of care. The applicability of position statements, as guidance for a procedure, must be determined by the responsible physician in light of all the circumstances presented by the individual patient. Adherence to these clinical position statements will not ensure successful treatment in every situation. As with all AAO-HNS/F guidance, this position statement should not be deemed inclusive of all proper treatment decisions or methods of care, nor exclusive of other treatment decisions or methods of care reasonably directed to obtaining the same results. Position statements are not intended to and should not be treated as legal, medical, or business advice.

AAO-HNS COVID-19 InformationLearn More